progressive renal damage (Anjaneyulu et al., 2004).
In our study, the increasing in serum urea levels
associated with the severity of diabetes, this finding
is in accordance with the fact that serum creatinine
and urea are used as important markers of Glomerular
Filtration Rate (GFR) (Deepa et al., 2011). Our study
is inline as well with the study that was conducted by
Sugam S et al that found that diabetic patients have
higher serum urea in compare to non-diabetic
patients. They reported that 18 out of 103 diabetes
samples have high urea level. An another study also
showed that the increase in mean values of serum urea
136.03 ± SD 74.6 mg/dl in kidney disease patients
with Diabetes mellitus (Mittal et al, 2010). The
increasing levels of serum urea is one of the
important measures of a damage in glomerular which
can, in no way be reversed by intensive treatment plan
of lowering glucose level in diabetic patients. The
only way to control the progressiveness of glomerular
damage and thereby increasing levels of serum urea
is the early detection and intervention.
4 CONCLUSION
The major cause of renal morbidity and mortalityis
DM, and diabetic nephropathy is one of the major
cause of chronic kidney failure. One of the indicator
that is widely used to examine the renal function
failure is blood urea and creatinine levels, it is simple
and useful biomarkers that can be a predictor test to
examine kidney functions (nephropathy) in DM
patients. Blood glucose levels that is in good control
helps to preventthe progressiveness of renal
impairment and one of major cause of chronic renal
failure which is diabetic nephropathy. The good
control of blood glucose level is the most important
requirement in preventing the progressiveness of
renal impairment. In order to monitor the control of
blood glucose level along with blood sugar blood urea
can also be important parameter as we found that
there is strong correlation of blood sugar and urea
level.
ACKNOWLEDGEMENT
The authors gratefully acknowledge that the present
research is supported by Ministry of Research and
Technology and Higher Education Republic
Indonesia, under research grant TALENTA USU of
Year 2018.
REFERENCES
Anderson, D., 2005. Harrison’s principles of internal
medicine.Neurology, 64(8), pp.1488-1489.
Anjaneyulu, M. and Chopra, K., 2004. Quercetin, an anti-
oxidant bioflavonoid, attenuates diabetic nephropathy
in rats.Clinical and Experimental pharmacology and
physiology, 31(4), pp.244-248.
Deepa, K., Manjunatha, G.B.K., Oinam, S.D., Devaki,
R.N., Bhavna, N., Asha, P. and Naureen, A., 2011.
Serum urea, creatinine in relation to fasting plasma
glucose levels in type 2 diabetic patients. International
journal of Pharmacy and Biological sciences, 1(3),
pp.279-283.
Gowda, S., Desai, P.B., Kulkarni, S.S., Hull, V.V., Math,
A.A. and Vernekar, S.N., 2010. Markers of renal
function tests.North American journal of medical
sciences, 2(4), p.170.
Kalra, S.P., 2012. A case for new therapy for diabetes, is it
leptin?. Indian journal of endocrinology and
metabolism,16(Suppl 3), p.S525.
Kamal, A., 2014. Estimation of blood urea (BUN) and
serum creatinine level in patients of renal
disorder. Indian J Fundam Appl Life Sci, 4(4), pp.199-
202.
Kanwar, G., Jain, N., Sharma, N., Shekhawat, M., Ahmed,
J. and Kabra, R., 2015. Significance of serum urea and
creatinine levels in type 2 diabetic patients. IOSR J
Dent Med Sci, 14(8), pp.65-7.
Kementrian Kesehatan, R.I., 2013. Riset kesehatan dasar
(Riskesdas) 2013. Jakarta: Badan Penelitian dan
Pengembangan Kesehatan.
Mehta, R.S., Karki, P. and Sharma, S.K., 2006. Risk
factors, associated health problems, reasons for
admission and knowledge profile of diabetes patients
admitted in BPKIHS.Kathmandu University Medical
Journal, 4(1), pp.11-13.
Melmed, S., 2016. Williams textbook of endocrinology.
Elsevier Health Sciences.
Mittal, A., Sathian, B., Kumar, A., Chandrasekharan, N.
and Sunka, A., 2010. Diabetes mellitus as a potential
risk factor for renal disease among Nepalese: A hospital
based case control study. Nepal journal of
epidemiology, 1(1), pp.22-25.
Rehman, G., Khan, S.A. and Hamayun, M., 2005. Studies
on diabetic nephropathy and secondary diseases in type
2 diabetes. Int. J. Diab. Dev. Ctries, 25, pp.25-29.
Smyth, S. and Heron, A., 2006. Diabetes and obesity: the
twin epidemics. Nature medicine, 12(1), p.75.
Wild, S., Roglic, G., Green, A., Sicree, R. and King, H.,
2004. Global prevalence of diabetes: estimates for the
year 2000 and projections for 2030. Diabetes
care, 27(5), pp.1047-1053.
Yach, D., Stuckler, D. and Brownell, K.D., 2006.
Epidemiologic and economic consequences of the
global epidemics of obesity and diabetes. Nature
medicine, 12(1), p.62.
Zimmet, P., Alberti, K.G.M.M. and Shaw, J., 2001. Global
and societal implications of the diabetes
epidemic. Nature,414(6865), p.782.